GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide
Integration allows people living with diabetes – with or without insurance – to access Sanofi’s most-prescribed insulin at a fixed rate anywhere GoodRx is accepted
Excerpt:
-GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in diabetes care, to offer a new way for people living with diabetes to access Lantus® (insulin glargine injection) 100 Units/mL in the U.S. for only $35.
“Sanofi believes that no one should struggle to pay for their insulin”
This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect January 1, 2024. It leverages GoodRx’s reach and scale to broaden access and affordability for people living with diabetes and means that, effective today, all Americans with a valid prescription, regardless of insurance status, can use GoodRx at over 70,000 U.S. retail pharmacies to access a 30-day supply of Lantus for only $35.
The number of Americans living with diabetes is increasing every year. Currently, an estimated 37.3 million Americans (approximately 11.3% of the U.S. population) have diabetes, and roughly 8.4 million of them use insulin, according to the American Diabetes Association.
********
This isn’t a better program than others available or if you have insurance. If you have insurance, not Medicare or Medicaid, any medicine on your policy’s formulary is $20.00 for 30 days supply. If you don’t have insurance and qualify for the patient assistance program a company offers the amount you would pay would be $ 0.00. Novo Nordsk and Lilly, Sanofi’s competitors, offer PAP that cost $ 0.00 if one qualifies. The $35.00 Sanofi is ‘offering’ matches what FJB’s Inflation Reduction Act capped insulin cost for Medicare at. So IMO this is a political publicity stunt by Sanofi and there are better less expensive options out there if one looks and researches.